Inhibitors of Stearoyl-Coenzyme A Desaturase 1 and 5 May Provide a Novel Therapeutic Strategy for the Treatment of Neurological Disorders and Brain Cancer [0.03%]
硬脂酰辅酶A去饱和酶1和5抑制剂可能为神经性疾病和脑癌的治疗提供新的策略
Ahmed F Abdel-Magid
Ahmed F Abdel-Magid
The invention in this patent application relates to heterocyclic compounds represented herein generally by formula 1. These compounds are inhibitors of stearoyl-coenzyme A desaturases (SCD1 and/or SCD5) and may provide a useful treatment fo...
Development of Purine and Pyrrolopyrimidine Scaffolds as Potent, Selective, and Brain Penetrant NUAK1 Inhibitors [0.03%]
开发嘌呤和吡咯并嘧啶支架作为有效的、选择性的和可以穿透大脑的NUAK1抑制剂
Gregory G Aldred,Helen K Boffey,Henriette M G Willems et al.
Gregory G Aldred et al.
NUAK1 is a protein kinase with various cellular functions including cell proliferation, migration and adhesion. NUAK1 has also been implicated in tau phosphorylation and stabilization leading to interest in this kinase as a therapeutic targ...
Novel Cyanotriazole Compounds for Treating Kinetoplastid Diseases, Particularly, Chagas Disease, Leishmaniasis, and Human African Trypanosomiasis [0.03%]
用于治疗动鞭毛虫病的新型氰基三唑化合物，特别是查加斯病、利什曼病和人类非洲锥虫病
Ram W Sabnis
Ram W Sabnis
Provided herein are novel cyanotriazole compounds, pharmaceutical compositions, use of such compounds in treating Chagas disease, leishmaniasis and human African trypanosomiasis (HAT), and processes for preparing such compounds. ...
Novel N‑Arylquinoline-4-carboxamide Derivatives as Prostaglandin F Receptor Antagonists [0.03%]
新型N-芳基喹啉-4-羧酰胺衍生物作为前列腺素F受体拮抗剂的研究
Steven H Liang
Steven H Liang
This patent highlight describes the development of novel substituted N-arylquinoline-4-carboxamide derivatives as potent, selective antagonists of the prostaglandin F (FP) receptors. The synthetic methods, pharmacological properties and the...
The Potential of the Alpha4 Beta7 Integrin Inhibitors as Treatment for Inflammatory Bowel Diseases and Related Disorders [0.03%]
α4β7整合素抑制剂治疗炎症性肠病及相关疾病的潜力
Ahmed F Abdel-Magid
Ahmed F Abdel-Magid
The invention in this patent application relates to compounds having structures represented generally herein by formula 1. These compounds are modulators of alpha 4 beta 7 integrin and may provide useful treatment for several inflammatory c...
Discovery of Novel Class of METTL3 Inhibitors with a Pyridin-2(1 H)‑one Moiety [0.03%]
一类具有吡啶并酮结构的新型METTL3抑制剂的发现
Weihang Zhang,Yuting Huang,Hong Yang et al.
Weihang Zhang et al.
N 6-Methyladenosine methylation (m6A) is the most common type of RNA modification and is catalyzed primarily by the METTL3-METTL14 methyltransferase complex. METTL3 is considered a promising target for the treatment of acute myeloid leukemi...
Novel 2 H‑Pyrazolo[3,4‑ d]thiazole Compounds Targeting NLRP3 for the Treatment of Neurodegenerative Diseases [0.03%]
用于治疗神经退行性疾病的新型2H-吡唑并[3,4-d]噻唑化合物类NLRP3抑制剂
Zhendong Song,Steven H Liang
Zhendong Song
The invention discloses novel NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inhibitors featuring a 2H-pyrazolo-[3,4-d]-thiazole scaffold. These NLRP3 inhibitors exhibit significant potential as therapeutic candidates for neurode...
LRRK2 Degraders for Parkinson's Disease and Inflammation: Tau and α‑Synuclein Degraders for Neurodegeneration [0.03%]
用于帕金森病和炎症的LRRK2降解剂：用于神经退行性疾病的Tau和α-突触核蛋白降解剂
Anna C Renner,Robert B Kargbo
Anna C Renner
Two complementary PROTAC classesbenzimidazole-anchored degraders of LRRK2 and pyrrolopyridine-based scaffolds for tau and α-synuclein clearancedemonstrate subnanomolar degradation potency, improved SAR over phthalimide comparators, and...
Novel Bicyclic Peptides Targeting Interleukin-23 Receptor to Relieve Inflammatory Conditions [0.03%]
靶向白细胞介素-23受体的新型双环肽缓解炎症状态
Qi-Long Hu,Steven H Liang
Qi-Long Hu
This patent application discloses a series of bicyclic peptides targeting the Interleukin-23 receptor (IL-23R), as represented by Formula I. These peptides exhibit significant therapeutic potential, particularly for the treatment of inflamm...
Correction to "The Bis(1,2,3,4-tetrahydroisoquinoline) Alkaloids Cepharanthine and Berbamine Are Ligands of SK Channels" [0.03%]
“双四氢异喹啉类生物碱 cepharanthine和berbamine是sk通道的配体”一文的更正
Romain Vitello,Hossein Taouba,Marine Derand et al.
Romain Vitello et al.
[This corrects the article DOI: 10.1021/acsmedchemlett.3c00452.]. © 2025 American Chemical Society.